Why Is SPYRE THERAPEUTICS I (SYRE) Stock Down Today?

SYRE stock fell 13.60% to $80.11 in a sharp decline driven by the announcement of a $350 million public offering at $85.00 per share. The offering, which includes a 30-day underwriters’ option for an additional $52.5 million, has raised concerns among investors about potential share dilution and market pressure. The move follows a broader 8.6% drop over the last eight sessions and comes amid a period of deteriorating sentiment and heavy insider selling.

What Happened

On October 5, 2026, Spyre Therapeutics announced the pricing of an underwritten public offering of 4,117,648 shares at $85.00 per share, with expected gross proceeds of approximately $350.0 million. The offering includes a 30-day option for underwriters to purchase up to an additional 617,648 shares, which would raise an additional $52.5 million. The news triggered immediate market pressure, with the stock falling below its offering price as investors reacted to the increased supply of shares. The offering is intended to fund the company’s gastroenterology, rheumatology, and dermatology programs. The announcement came after insider sales totaling $16.9 million over the past 90 days, with recent transactions by the CEO, CFO, and other executives on September 30 and October 1.

What The Data Shows

The stock has declined 6.8% over the past eight sessions, from $86.00 to $80.11, and hit 21 fresh 52-week lows on October 6. The company has a market capitalization of $8.2 billion but remains unprofitable, with a trailing twelve-month (TTM) earnings per share (EPS) of -2.01 and a TTM revenue decline of 100.0%. The stock’s beta of 3.00 indicates high volatility, and its 52-week range is $15.86 to $110.17. The offering price of $85.00 is significantly below the 52-week high but above the current price, suggesting immediate market skepticism. The stock’s recent performance has also been marked by deteriorating sentiment, with a 30-day average of 43/100 and a 7-day average of 38/100.

What To Watch

The company has no scheduled earnings date in the near term, but investors should monitor the breadth of coverage and any further insider transactions. The market will likely remain sensitive to developments in the offering and how the capital is allocated across the company’s therapeutic programs.